Orange, CA (openPR) 1 October 2010

In the ongoing fight against breast cancer fight, thousands of physicians and scientists devote their time and often their entire career research a cure. Some of them to achieve fame, others prefer a degree of anonymity outside of their circle of fellow researchers, but may still be regarded as a powerful authority. Lnx Pharma, a market research firm, specializing in key opinion leaders in the pharmaceutical industry, has published his Top 20 list of most influential people in the field of research on breast cancer.

Almost half of the list is the United States (nine of the top 20), with the UK contribution to the four – perhaps not surprisingly, given the increasing amount of research dollars from these countries. Nearly all (80%) of medical degrees, and most doctors in the task list at the universities. Many are “Rising Stars”, which means they are beginning their careers, but have already gained considerable respect from colleagues and the press.

lnx Global Pharma Top 20 are the most influential researchers in breast cancer:

Gabriel Hortobà ¡gyi, MD – Department of Medical Oncology within the University of Texas MD Anderson Cancer Center (USA)
Ian Ellis, MD, PhD – Molecular Medicine, Department of Histopathology, University of Nottingham, Nottingham City Hospital NHS Trust (UK)
Eric Winer, MD – Director, Breast Oncology Center, Director of Women’s cancers, Thompson Principal Investigator in the research of breast cancer, Dana-Farber Cancer Institute (USA)
Judy Garber, MD – Director, Cancer Risk Factors and Prevention, Dana-Farber Cancer Institute (USA)
Nadia Harbeck, MD, Ph.D. – Head of the Breast Center, University of Cologne (Germany)
Martine Piccart-Gebhart, MD, PhD – Associate Professor of Oncology at the Free University of Brussels (Belgium)
Mitch Dowsett, Ph.D. – Professor of Biochemical Endocrinology, Head of the Academic Department of Biochemistry and Director of Translational Research in Breast Cancer, Royal Marsden Hospital and Institute of Cancer Research (UK)
Klijn Jan, MD, PhD – Department of Medical Oncology, Rotterdam Cancer Institute (Netherlands)
Fergus Couch, PhD – Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic (USA)
Susan Domchek, MD – Abramson Cancer Center, University of Pennsylvania School of Medicine (USA)
Professor, Department of Internal Medicine, University of Michigan Health System (USA) – Daniel Hayes, MD
James Ingle, MD – Director, Research Program on Breast Cancer, Mayo Medical School (USA)
Charles Peru, Ph.D. – Associate Professor, School of Medicine at UNC (USA)
Aman Buzdar, MD – Professor of Medicine, University of Texas MD Anderson Cancer Center (USA)
Hironobu Sasano, MD, PhD – Institute of Pathology, Faculty of Medicine, Tohoku University (Japan)
Kathy Pritchard, MD – Sunnybrook Odette Cancer Center, University of Toronto (Canada)
Marc van de Vijver, MD, PhD – Division of oncology diagnosis, Netherlands Cancer Institute (Netherlands)
Easton Douglas, Ph.D. – CR-UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge (UK)
Rita Schmutzler, MD – Center for Familial Breast and Ovarian Cancer, University Hospital of Cologne (Germany)
David Cameron, MD – Department of Oncology, University of Edinburgh, Western General Hospital (UK)

methodology

There are many controversies about how to “mark” the value of an expert or opinion leader, particularly in medical research. Typically, a series of quotations from the literature and addresses is used to measure the impact. Instead, lnx pharmaceutical complex scoring method is based on social network analysis, a science, that people who are most deeply and widely to a network connected the greatest probability of acceptance of their ideas and recognize innovation through exposure to new ideas.

lnx Pharma publishes more than 20,000 articles analyzed in the last three years, linked with breast cancer to determine the industry term for breast cancer, and references to literature with multiple data points, relationships. More than 44,000 people were tested in the so-called “giant component” or communal basis of cancer. After the analysis of who these people were, they of the value of people and the strength of these relationships, more than 600 people as an “invisible college” is the term for a collection lnx Pharma was founded in context, people with close relationships to each other together by many things.

occur, it is fascinating to see a map of the network, especially in a large pool of researchers is to breast cancer, “said Philip Topham, Director General of lnx Pharma. “You can literally see the emergence of trends relating to people and geographical areas and certain segments in the study. This usually comes at the end not just a list of names, but in fact, a topographical map, which in by pharmaceutical companies and governments their strategies can be used. refine pharmaceutical engagement strategies so that they have the right to opinion leaders for their scientific advisory boards and the need for further consultation. Governments can develop test the impact of their funding for new partnerships to fill gaps and the results improve. “

lnx Pharma has 50 diseases in just three years analyzed the activity, in collaboration with leading pharmaceutical companies, which use the company’s capabilities to isolate unknown key opinion leaders and present the evaluation of the KOL force were engaged in managerial activities. The objectivity of the analysis considers the strict enforcement of laws and compliance Sunshine Act applied to the pharmaceutical industry.


About Pharma

lnx

lnx Pharma is a research division of lnx, LLC, a privately held company in Orange, California, which provide tours in the analysis of knowledge communities. Lnx property research uses social network analysis methods and technologies to identify and understand “The Invisible College” key opinion leaders on issues of knowledge communities for government and commercial customers in various industries to answer. For White Papers on the topic, or to get information about lnx Pharma, go to www.lnxpharma.com.

Keywords:

Breast Cancer Awareness Month breast cancer, tumors of the breast, medical research, management of key opinion leaders, mapping the influence of the pharmaceutical market research, the map of the influence of the alliance, the mapping project impact, influence mapping glycol, pharmaceutical research, social network analysis, SNA, kol, kol-management, opinion leaders

# # #

clear = “all”
Acne drug cons